Skip to main content

Market Overview

Novo Nordisk Shares Gain On Fourth Quarter Earnings Beat, Stock Repurchase Program

  • Novo Nordisk A/S (NYSE: NVO) posted better than expected fourth-quarter earnings but said that sales growth was negatively impacted by COVID-19, driven by fewer patients initiating treatment, due to social-distancing regulations. The company also said that for continuing trials, recruitment of new patients is still below pre-coronavirus levels.
  • The fourth quarter had strong sales growth within diabetes and obesity care, partially offset by lower insulin sales, fewer new patients due to COVID-19, higher unemployment in the U.S., and COVID-related destocking.
  • The quarter's net profit rose to DKK 9.32 billion, while sales slipped at a rate of 0.9% to DKK 32.1 billion.
  • The company expects full-year 2021 annual sales growth of 5% to 9% and operating profit growth of 4% to 8% in local currencies, reflecting sales growth of diabetes-care products Ozempic and Rybelsus as well as growth within obesity care.
  • The board proposed a final dividend of DKK5.85 a share for 2020 and intends to initiate a new 12-month share repurchase program of up to DKK 17 billion.
  • NVO shares increased 3.8% at $73.65 in pre-market trading on the last check Wednesday.

Related Articles (NVO)

View Comments and Join the Discussion!

Posted-In: Covid-19Earnings News Guidance Health Care Buybacks General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at